Sunshine Biopharma Inc. (SBFM)

Price$2.46

Growth ScoreC

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-90.95%

Price vs S&P 500 (4W)-76.56%

VGM Score35.96

Market Capitalization$5.22M

All Metrics

Book Value / Share (Quarterly)$43.86

P/TBV (Annual)0.29x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)102.91%

Cash Flow / Share (Quarterly)$-13.08

Price vs S&P 500 (YTD)-88.16%

Gross Margin (TTM)32.98%

Net Profit Margin (TTM)-17.02%

EPS (TTM)$-9.28

10-Day Avg Trading Volume2.01M

EPS Excl Extra (TTM)$-9.28

Revenue Growth (5Y)248.13%

EPS (Annual)$-14.37

ROI (Annual)-25.94%

Gross Margin (Annual)33.76%

Net Profit Margin (5Y Avg)-1223.93%

Cash / Share (Quarterly)$14.09

Revenue Growth QoQ (YoY)-9.13%

ROA (Last FY)-19.87%

Revenue Growth TTM (YoY)-2.05%

EBITD / Share (TTM)$-4.04

ROE (5Y Avg)-1211.75%

Operating Margin (TTM)-17.83%

Cash Flow / Share (Annual)$-12.57

P/B Ratio0.24x

P/B Ratio (Quarterly)0.24x

Net Income / Employee (Annual)$-119,500

EV / Revenue (TTM)-0.05x

Net Interest Coverage (TTM)-37.74x

ROA (TTM)-19.89%

EPS Incl Extra (Annual)$-14.37

Current Ratio (Annual)4.17x

Quick Ratio (Quarterly)1.87x

3-Month Avg Trading Volume1.09M

52-Week Price Return-83.38%

Revenue / Employee (TTM)$709,900

Tangible BV / Share (Quarterly)$39.95

P/S Ratio (Annual)0.14x

Asset Turnover (Annual)1.21x

52-Week High$24.30

Operating Margin (5Y Avg)-1197.75%

EPS Excl Extra (Annual)$-14.37

CapEx CAGR (5Y)270.37%

26-Week Price Return-83.02%

Quick Ratio (Annual)1.95x

13-Week Price Return-78.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.22x

Enterprise Value$-1.69M

Revenue / Share Growth (5Y)65.19%

Asset Turnover (TTM)1.17x

Revenue / Employee (Annual)$726,100

Inventory Turnover (Annual)1.94x

Pretax Margin (Annual)-16.40%

Cash / Share (Annual)$18.60

3-Month Return Std Dev235.99%

Gross Margin (5Y Avg)37.34%

Net Income / Employee (TTM)$-120,800

ROE (Last FY)-25.94%

Net Interest Coverage (Annual)-8.18x

EPS Basic Excl Extra (Annual)$-14.37

Receivables Turnover (TTM)9.52x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-9.28

Receivables Turnover (Annual)9.91x

ROI (TTM)-25.58%

P/S Ratio (TTM)0.15x

Pretax Margin (5Y Avg)-1222.65%

Revenue / Share (Annual)$87.33

Tangible BV / Share (Annual)$43.11

Price vs S&P 500 (52W)-107.74%

Year-to-Date Return-80.00%

5-Day Price Return2.93%

EPS Normalized (Annual)$-14.37

ROA (5Y Avg)-141.82%

Net Profit Margin (Annual)-16.46%

Month-to-Date Return-3.15%

Cash Flow / Share (TTM)$-1.09

EBITD / Share (Annual)$-14.18

Operating Margin (Annual)-17.15%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-156.30%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-9.28

P/TBV (Quarterly)0.26x

P/B Ratio (Annual)0.26x

Inventory Turnover (TTM)1.90x

Pretax Margin (TTM)-16.84%

Book Value / Share (Annual)$46.96

Price vs S&P 500 (13W)-86.68%

Beta-8.39x

Revenue / Share (TTM)$72.35

ROE (TTM)-25.58%

52-Week Low$2.11

gGradeC

mGradeF

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.25est. —

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SBFMSunshine Biopharma Inc.	—	C	F	$2.46
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Sunshine Biopharma Inc is a pharmaceutical company operating across oncology and antiviral therapeutics, with a commercial portfolio of generic prescription drugs in Canada and over-the-counter supplements. The company is developing a proprietary pipeline including K1.1, an mRNA therapeutic targeting liver cancer, and SBFM-PL4, a protease inhibitor candidate for SARS coronavirus infections.